Abstract
In previous studies of the pharmacokinetics and urinary excretion of nine glycopeptides with diverse isoelectric points (pI),as pIdecreases, the total systemic and renal clearance, urinary recovery, and volume of distribution decrease, whereas the half-life increases. With glycopeptides of similar pI,clearance decreases and half-life increases with increasing lipophilicity. The present study examines the serum protein binding of these glycopeptide antibiotics in mouse, rat, and human serum and calculates the previously reported pharmacokinetic parameters for these drugs based on unbound concentration. Increased negative charge and lipophilicity increase serum protein binding (90-fold, fu 83% to 0.96%), which decreases the renal clearance and total systemic clearance (90-fold, 16.4 to 0.18 ml/min/kg) of these drugs. Increased serum protein binding also decreases the volume of distribution of these compounds, but this change is relatively small (sixfold, 755 to 131 ml/kg) compared with the change in total systemic clearance causing an increase in elimination half-life (25-fold, 20 to 492 min). The results demonstrate that the large differences in the total systemic clearance and half-life of these glycopeptide antibiotics are primarily due to dramatic differences in serum protein binding and notto differences in the intrinsic elimination processes (enzymes or transport proteins). It appears that the same physical-chemical properties that govern the protein binding and pharmacokinetics of small organic molecules govern the disposition of these high-molecular weight glycopeptide antibiotics.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
W. A. Craig and P. G. Welling. Protein binding of antimicrobials, clinical pharmacokinetics and therapeutic implications.Clin. Pharmacokinet. 2: 252–268 (1976).
W. J. Jusko and M. Gretch. Plasma and tissue protein binding of drugs in pharmacokinetics.Drug Metab. Rev. 5:43–140 (1976).
W. J. Jusko. Guidelines for collection and pharmacokinetic analysis of drug disposition data. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.),Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Applied Therapeutics, Spokane, 1980, p. 639.
M. C. Shearer, P. Actor, B. A. Bowie, S. F. Grappel, C. H. Nash, D. J. Newman, Y. K. Oh, C. H. Pan, and L. J. Nisbet. Aridicins, novel glycopeptide antibiotics. I. Taxonomy, production and biological activity.J. Antibiot. 38:555–560 (1985).
R. D. Sitrin, G. W. Chan, J. J. Dingerdissen, W. Hill, J. R. E. Hoover, J. R. Valenta, L. Webb, and K. M. Snader. Aridicins, novel glycopeptide antibiotics. II. Isolation and characterization.J. Antibiot. 38:561–571 (1985).
R. D. Sitrin, G. W. Chan, A. J. Giovenella, S. F. Grappel, P. W. Jeffs, L. Phillips, K. M. Snader, and L. J. Nisbet. Aridicins, novel glycopeptides antibiotics: III. Preparation, characterization, and biological activities of aglycone derivatives.J. Antibiot. 39:69–75 (1986).
P. W. Jeffs, G. Chan, R. Sitrin, N. Holder, and C. DeBrosse. The structure of glycolipid components of the aridicin antibiotic complex.J. Org. Chem. 50:1726–1731 (1986).
P. W. Jeffs, G. Chan, G. Roberts, C. DeBrosse, L. Mueller, L. Webb, L. Killmer, and R. D. Sitrin. Degradation studies on the aridicin aglycone. Isolation and characterization of the constituent amino acids.J. Org. Chem.,51:4272–4278 (1986).
P. W. Jeffs, L. Mueller, C. DeBrosse, S. Heald, and R. Fisher. The structure of aridicin A. An integrated approach employing 2-D NMR, energy minimization and distance constraints.J. Am. Chem. Soc. 108:3063–3075 (1986).
D. H. Pitkin, B. A. Mico, R. D. Sitrin, and L. J. Nisbet. Charge and lipophilicity govern the pharmacokinetics of glycopeptide antibiotics.Antimicrobial Agents Chemother. 29:440–444 (1986).
F. D. Boudinot and W. J. Jusko. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis.J. Pharm. Sci. 73:774–780 (1984).
S. Øie and T. N. Tozer. Effect of altered plasma protein binding on apparent volume of distribution.J. Pharm. Sci. 68:1203–1205 (1979).
P. H. Hinderling, O. Schmidlin, and J. K. Seydel. Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.J. Pharmacokin. Biopharm. 12:263–287 (1984).
J. K. Seydei and K. J. Schaper. Quantitative structure-pharmacokinetic relationships and drug design. In M. Rowland and G. Tucker (eds.),Pharmacology and Therapeutics, Vol. 15, Permagon Press, Elmford, New York, 1982, p. 131.
S. Toon and M. Rowland. Structure-Pharmacokinetic relationships among barbiturates in the rat.J. Pharmacol. Exp. Ther. 225:752–762 (1983).
J. K. Seydel, D. Trettin, O. Wasserman, and M. Makiusz. Quantitative structure-pharmacokinetic relationships derived on sulfonamides in rats and its comparison to structure-activity relationships.J. Med. Chem. 23:607–613 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wittendorf, R.W., Swagzdis, J.E., Gifford, R. et al. Protein binding of glycopeptide antibiotics with diverse physical-chemical properties in mouse, rat, and human serum. Journal of Pharmacokinetics and Biopharmaceutics 15, 5–13 (1987). https://doi.org/10.1007/BF01062935
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01062935